<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02066012</url>
  </required_header>
  <id_info>
    <org_study_id>CHU-0180</org_study_id>
    <secondary_id>2013-A01687-38</secondary_id>
    <nct_id>NCT02066012</nct_id>
  </id_info>
  <brief_title>MEPHISTO (Macrophage Phenotype In Metabolic Syndrome With Iron Overload)</brief_title>
  <acronym>MEPHISTO</acronym>
  <official_title>Impact of Dysmetabolic Iron Overload Syndrome on Polarization Capacity of Macrophages</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Recherche Agronomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      Dysmetabolic iron overload syndrome (DIOS), is a frequent hepatic iron overload associated&#xD;
      with metabolic syndrome. We hypothesize that this mild iron overload can induce a increased&#xD;
      macrophagic polarization towards inflammatory types, thereby contributing to cardiovascular&#xD;
      risk. Our main objective is to highlight the influence of iron overload on polarization&#xD;
      capacity of monocytes into alternative macrophages (called M2). We therefore compare&#xD;
      phenotypic markers of monocytes/macrophages between subjects with DIOS, metabolic syndrome&#xD;
      without iron overload and lean subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MEPHISTO is a pathophysiological, transverse, case-control, single-center study (university&#xD;
      hospital, Clermont-Ferrand, France). No intervention (drug or nutritional) is conducted as&#xD;
      part of this study and the participants are not subject to any exclusion period. Our&#xD;
      objective is to investigate the effects of iron overload on monocyte/macrophage polarization&#xD;
      and its relations with the cardiovascular risk factors.&#xD;
&#xD;
      We study 60 subjects divided into 3 groups of 20 participants :&#xD;
&#xD;
        -  group DIOS composed of subjects with dysmetabolic hepatosiderosis&#xD;
&#xD;
        -  group M composed of subjects with metabolic syndrom without iron overload&#xD;
&#xD;
        -  group T composed of lean subjects DIOS group participants were selected among patients&#xD;
           recently diagnosed as DIOS, without any secondary hyperferritinemia and with hepatic&#xD;
           iron overload proved by liver MRI.&#xD;
&#xD;
      Recruitement of group DIOS was carried out in the internal medicine service. Subjects of&#xD;
      group M and DIOS come from the file of volunteers from the center of clinical investigation&#xD;
      (CIC-501, Clermont-Ferrand). Subject of group M to group DIOS are matched by age, gender (+/-&#xD;
      5 kg/m²) and BMI. Subjects of group T to group DIOS are matched by age and gender. As no&#xD;
      direct benefit is expected for the participants, they receive a lump sum compensation of 50&#xD;
      euros.&#xD;
&#xD;
      Each participant undergoes only a 1 hour consultation including a clinical examination and&#xD;
      blood sample.&#xD;
&#xD;
      We focus on clinical parameters of the metabolic syndrome (waist size, BMI, blood pressure)&#xD;
      and on seeking exclusion factors (infection, neoplasia, anti-inflammatory drugs). Due to&#xD;
      their potential influence on inflammation and oxidant stress, these factors, as same as&#xD;
      smoking were excluded.&#xD;
&#xD;
      Blood sample will be used to perform:&#xD;
&#xD;
        -  classical laboratory test (blood count, reticulocytes, ASAT, ALAT, LDH, lipid profile,&#xD;
           glycemia, insulinemia, TSH, , vitamin D, ferritin, transferrin saturation, CRP),&#xD;
&#xD;
        -  specific dosages (IL-6, TNFalpha, hepcidine) by ELISA,&#xD;
&#xD;
        -  monocyte phenotype ( CD14, CD16, CD 163, MR) by FACS (Fluorescence Activated Cell&#xD;
           Sorting),&#xD;
&#xD;
        -  measurement of the gene expression from monocytes and macrophages after culturing by&#xD;
           real-time PCR.&#xD;
&#xD;
      Our main analysis focus on ex vivo polarization of monocytes into alternative macrophages&#xD;
      (M2) and phenotypic characterization. Before and after culturing monocytes with (to induce M2&#xD;
      macrophage) or without IL-4 (to induce resident macrophage), we will measure the expression&#xD;
      of phenotypic markers of polarization (MR, CD200R, F13A1, CD163, AMAC1, TGFb), inflammatory&#xD;
      markers (TNFα , MCP- 1, IL-6) , oxidative stress markers (HO- 1 ), and markers of iron&#xD;
      metabolism (ferroportin, ferritin, hepcidin). We use quantitative PCR microfluidic card&#xD;
      (TLDA, Taqman Low-Density Array) to measure gene expression of monocytes and type M2&#xD;
      macrophages. This technique allows screening of expression for 24 genes. Different phases are&#xD;
      required: RNA extraction (RNeasy kit, Qiagen), the reverse transcription (RT-PCR kit, HighCap&#xD;
      cDNA RT kit, Applied Biosystems), amplification (TaqMan Fast Advanced Master Mix, Applied&#xD;
      Biosystems), and finally the study of gene expression (MFC TaqMan Array for GeneEx, Format&#xD;
      24, Applied Biosystems). Our main outcome is capacity of polarization in M2 macrophages&#xD;
      evidenced by expression of MR, CD200R, F13A1, CD163, AMAC1, TGFb. Evaluating the influence of&#xD;
      iron overload on data from the clinical examination, the results of standard biology and&#xD;
      monocyte gene expression is our secondary outcome.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Expression (RNA) of macrophagic polarization markers</measure>
    <time_frame>at day 1</time_frame>
    <description>Expression (RNA) of macrophagic polarization markers (MR, CD200R, F13A1, CD163, AMAC1, TGFβ), among subjects with or without iron overload</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>characteristics of the subjects</measure>
    <time_frame>at day 1</time_frame>
    <description>Statistical relationships between monocyte phenotype and clinical (metabolic abnormalities) or biological (level of iron overload, oxidative stress and insulino-resistance) characteristics of the subjects.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Dysmetabolic Iron Overload Syndrome</condition>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>group DIOS</arm_group_label>
    <description>group DIOS composed of subjects with dysmetabolic hepatosiderosis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group M</arm_group_label>
    <description>group M composed of subjects with metabolic syndrom without iron overload</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group T</arm_group_label>
    <description>group T composed of lean subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dysmetabolic iron overload syndrome</intervention_name>
    <arm_group_label>group DIOS</arm_group_label>
    <arm_group_label>group M</arm_group_label>
    <arm_group_label>group T</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        metabolic syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  • 18 years old and over&#xD;
&#xD;
               -  written consent&#xD;
&#xD;
               -  for groups M and HSD at least one criteria of the metabolic syndrome definition&#xD;
                  according to the International Diabetes Federation&#xD;
&#xD;
               -  for group M only hepatic iron overload mesured by IRM (above 50 µmol/g)&#xD;
                  hyperferritnemia between 450 and 1500 µg/l&#xD;
&#xD;
               -  for group T only BMI &lt; 25 kg/m² Waist size &lt; 80 cm for women and &lt;94 cm for men&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  persons under guardianship&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  active smoking&#xD;
&#xD;
          -  current inflammatory or cancerous disease&#xD;
&#xD;
          -  hereditary hemochromatosis&#xD;
&#xD;
          -  use of anti-inflammatory, immunosuppressive or hypoglycaemic drugs&#xD;
&#xD;
          -  hemolysis&#xD;
&#xD;
          -  alcool consumption above 14 doses for women and 21 doses for men per week&#xD;
&#xD;
          -  history of therapeutic phlebotomy&#xD;
&#xD;
          -  inflammatory syndrome with CRP above 15 mg/l&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc RUIVARD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick LACARIN</last_name>
    <phone>04 73 75 11 95</phone>
    <email>placarin@chu-clermontferrand.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Clermont-Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick LACARIN</last_name>
      <phone>04 73 75 11 95</phone>
      <email>placarin@chu-celrmontferrand.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 14, 2014</study_first_submitted>
  <study_first_submitted_qc>February 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>February 17, 2014</last_update_submitted>
  <last_update_submitted_qc>February 17, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dysmetabolic Iron Overload Syndrome</keyword>
  <keyword>Metabolic Syndrome X</keyword>
  <keyword>Iron</keyword>
  <keyword>Monocyte</keyword>
  <keyword>Macrophage</keyword>
  <keyword>Polarization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Microvascular Angina</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Iron Overload</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

